Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,724.44
(
-1.69%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,037.76
(
-3.93%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: kamehameha post# 141875

Monday, 05/14/2012 11:36:44 AM

Monday, May 14, 2012 11:36:44 AM

Post# of 257257

VRTX/JAK class—[Biotech Jim]: initially starting with non-selective agents and then getting more selective…

[kamehameha]: that's why the JAK3 inhibitor VX-509 is a good bet!

It’s premature to say this, IMO. JAK3 specificity could turn out to be why VX-509 is a bad bat relative to the other JAK inhibitors in development.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now